Is universal antifungal prophylaxis mandatory in lung transplant patients?

Current Opinion in Infectious Diseases

Volumn 26, Issue 4, 2013, Pages 317-325

  Schaenman, Joanna M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

aerosolized amphotericin; aspergillosis; invasive fungal infection; itraconazole; lung transplantation; posaconazole; prophylaxis; voriconazole

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; ECHINOCANDIN; ITRACONAZOLE; POSACONAZOLE; VORICONAZOLE;

ANTIFUNGAL PROPHYLAXIS; BRONCHIOLITIS OBLITERANS; DERMATITIS; DRUG COST; DRUG MONITORING; DRUG TOLERANCE; FUNGAL COLONIZATION; GRAFT RECIPIENT; HIGH RISK PATIENT; HUMAN; INVASIVE ASPERGILLOSIS; LUNG TRANSPLANTATION; MENTAL HEALTH; MORTALITY; MULTICENTER STUDY (TOPIC); MYCOSIS; NONHUMAN; PERIOSTITIS; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SIDE EFFECT; SKIN CANCER; STEROID THERAPY; SYSTEMIC MYCOSIS; TRACHEOBRONCHITIS; TREATMENT DURATION; VISION;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; HUMANS; LUNG TRANSPLANTATION; MYCOSES;

EID: 84879887804     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e3283630e67     Document Type: Review

References (80)

1. Covarrubias MB, Milstone AP. An overview of fungal prophylaxis in lung transplantation. Curr Opin Organ Transplant 2005; 10:227-232. (Pubitemid 41335782)
2. Christie JD, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: 29th adult lung and heart-lung transplant report-2012. J Heart Lung Transplant 2012; 31:1073-1086.
3. Solé A, Morant P, Salavert M, et al., the Valencia Lung Transplant Group. Aspergillus infections in lung transplant recipients: risk factors and outcome. Clin Microbiol Infect 2005; 11:359-365. (Pubitemid 40575818)
4. Weigt SS, Elashoff RM, Huang C, et al. Aspergillus colonization of the lung allograft is a risk factor for bronchiolitis obliterans syndrome. Am J Transplant 2009; 9:1903-1911.
5. Magill SS, Dropulic LK. Antifungal prophylaxis in transplant recipients: where do we go from here? Transpl Infect Dis 2006; 8:187-189. (Pubitemid 44801435)
6. Pappas PG, Alexander BD, Andes DR, et al. Invasive fungal infections among organ transplant recipients: Results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis 2010; 50:1101-1111.
7. Neofytos D, Fishman JA, Horn D, et al. Epidemiology and outcome of invasive fungal infections in solid organ transplant recipients. Transplant Infect Dis 2010; 12:220-229.
8. Singh NM, Husain S, the AST Infectious Diseases Community of Practice. Aspergillosis in solid organ transplantation. Am J Transplant 2013; 13:228-241.
9. Gordon SM, Avery RK. Aspergillosis in lung transplantation: incidence, risk factors, and prophylactic strategies. Transpl Infect Dis 2001; 3:161-167. (Pubitemid 32756698)
10. Husni RN, Gordon SM, Longworth DL, et al. Cytomegalovirus infection is a risk factor for invasive aspergillosis in lung transplant recipients. Clin Infect Dis 1998; 26:753-755. (Pubitemid 28155032)
11. Singh N, Husain S. Aspergillus infections after lung transplantation: clinical differences in type of transplant and implications for management. J Heart Lung Transplant 2003; 22:258-266. (Pubitemid 36300817)
12. Solé A, Salavert M. Fungal infections after lung transplantation. Transplant Rev 2008; 22:89-104. (Pubitemid 351372918)
13. Chambers DC, Yerkovich ST, Maliyasena V, et al. Risk factors for invasive fungal infection after lung transplantation. J Heart Lung Transplant 2012; 31:S143-S144.
14. Schaenman JM, Rosso F, Austin JM, et al. Trends in invasive disease due to Candida species following heart and lung transplantation. Transplant Infect Dis 2009; 11:112-121.
15. Eriksson M, Lemström K, Suojaranta-Ylinen R, et al. Control of early aspergillus mortality after lung transplantation: outcome and risk factors. Transplant Proc 2010; 42:4459-4464.
16. Wahidi MM. Diagnosis and outcome of early pleural space infection following lung transplantation. Chest 2009; 135:484.
17. Husain S, Mooney ML, Danziger-Isakov L, et al. A 2010 working formulation for the standardization of definitions of infections in cardiothoracic transplant recipients. J Heart Lung Transplant 2011; 30:361-374.
18. Iversen M, Burton CM, Vand S, et al. Aspergillus infection in lung transplant patients: incidence and prognosis. Eur J Clin Microbiol Infect Dis 2007; 26:879-886. (Pubitemid 350077208)
19. Kubak BM, Huprikar SS, the AST Infectious Diseases Community of Practice. Emerging & rare fungal infections in solid organ transplant recipients. Am J Transplant 2009; 9:S208-S226.
20. Nucci M. Emerging moulds: Fusarium, Scedosporium and Zygomycetes in transplant recipients. Curr Opin Infect Dis 2003; 16:607-612.
21. Hosseini-Moghaddam SM, Husain S. Fungi and molds following lung transplantation. Semin Respir Crit Care Med 2010; 31:222-233.
22. Nivoix Y, Velten M, Letscher Bru V, et al. Factors associated with overall and attributable mortality in invasive aspergillosis. Clin Infect Dis 2008; 47:1176-1184.
23. Segal BH, Walsh TJ. Current approaches to diagnosis and treatment of invasive aspergillosis. Am J Respir Crit Care Med 2006; 173:707-717.
24. Sherif R, Segal BH. Pulmonary aspergillosis: clinical presentation, diagnostic tests, management and complications. Curr Opin Pulm Med 2010; 16:242-250.
25. Felton TW, Roberts SA, Isalska B, et al. Isolation of Aspergillus species from the airway of lung transplant recipients is associated with excess mortality. J Infect 2012; 65:350-356.
26. Garantziotis S, Palmer SM. An unwelcome guest: aspergillus colonization in lung transplantation and its association with bronchiolitis obliterans syndrome. Am J Transplant 2009; 9:1705-1706.
27. Weigt SS, Copeland CAF, Derhovanessian A, et al. Colonization with small conidia aspergillus species is associated with bronchiolitis obliterans syndrome: a two-center validation study. Am J Transplant 2013; 13:919-927.
28. Belperio JA, Keane MP, Burdick MD, et al. Critical role for CXCR3 chemokine biology in the pathogenesis of bronchiolitis obliterans syndrome. J Immunol 2002; 169:1037-1049. (Pubitemid 34753464)
29. Belperio JA, Weigt SS, Fishbein MC, Lynch JP. Chronic lung allograft rejection: mechanisms and therapy. Proc Am Thorac Soc 2009; 6:108-121.
30. Husain S, Raza K, Pilewski JM, et al. Experience with immune monitoring in lung transplant recipients: correlation of low immune function with infection. Transplantation 2009; 87:1852-1857.
31. Singh N, Husain S, the AST Infectious Diseases Community of Practice. Invasive aspergillosis in solid organ transplant recipients. Am J Transplant 2009; 9:S180-S191.
32. Neoh CF, Snell GI, Kotsimbos T, et al. Antifungal prophylaxis in lung transplantation: a world-wide survey. Am J Transplant 2011; 11:361-366.
33. Husain S, Zaldonis D, Kusne S, et al. Variation in antifungal prophylaxis strategies in lung transplantation. Transplant Infect Dis 2006; 8:213-218. (Pubitemid 44787860)
34. Dummer JS, Lazariashvilli N, Barnes J, et al. A survey of antifungal management in lung transplantation. J Heart Lung Transplant 2004; 23:1376-1381. (Pubitemid 40018160)
35. Levine SM. Transplant/Immunology Network of the American College of Chest Physicians: a survey of clinical practice of lung transplantation in North America. Chest 2004; 125:1224-1238.
36. Shitrit D, Ollech JE, Ollech A, et al. Itraconazole prophylaxis in lung transplant recipients receiving tacrolimus (FK 506): efficacy and drug interaction. J Heart Lung Transplant 2005; 24:2148-2152. (Pubitemid 41814739)
37. Cadena J, Levine DJ, Angel LF, et al. Antifungal prophylaxis with voriconazole or itraconazole in lung transplant recipients: hepatotoxicity and effectiveness. Am J Transplant 2009; 9:2085-2091.
38. Husain S, Paterson DL, Studer S, et al. Voriconazole prophylaxis in lung transplant recipients. Am J Transplant 2006; 6:3008-3016.
39. Mitsani D, Nguyen MH, Shields RK, et al. Prospective, observational study of voriconazole therapeutic drug monitoring among lung transplant recipients receiving prophylaxis: factors impacting levels of and associations between serum troughs, efficacy, and toxicity. Antimicrob Agents Chemother 2012; 56:2371-2377.
40. Tofte N, Jensen C, Tvede M, et al. Use of prophylactic voriconazole for three months after lung transplantation does not reduce infection with Aspergillus: a retrospective study of 147 patients. Scand J Infect Dis 2012; 44:835-841.
41. Reichenspurner H, Gamberg P, Nitschke M, et al. Significant reduction in the number of fungal infections after lung-, heart-lung, and heart transplantation using aerosolized amphotericin B prophylaxis. Transplant Proc 1997; 29: 627-628. (Pubitemid 27123555)
42. Calvo V, Borro JM, Morales P, et al., the Valencia Lung Transplant Group. Antifungal prophylaxis during the early postoperative period of lung transplantation. Chest 1999; 115:1301-1304. (Pubitemid 29230637)
43. Monforte V, Román A, Gavalda J, et al. Nebulized amphotericin B prophylaxis for Aspergillus infection in lung transplantation: study of risk factors. J Heart Lung Transplant 2001; 20:1274-1281. (Pubitemid 34017312)
44. Drew RH, Dodds Ashley E, Benjamin DK Jr, et al. Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients. Transplantation 2004; 77:232-237. (Pubitemid 38155752)
45. Lowry CM, Marty FM, Vargas SO, et al. Safety of aerosolized liposomal versus deoxycholate amphotericin B formulations for prevention of invasive fungal infections following lung transplantation: a retrospective study. Transplant Infect Dis 2007; 9:121-125. (Pubitemid 46669088)
46. Borro JM, Solé A, la Torre de M, et al. Efficiency and safety of inhaled amphotericin B lipid complex (Abelcet) in the prophylaxis of invasive fungal infections following lung transplantation. Transplant Proc 2008; 40:3090-3093.
47. Monforte V, Ussetti P, Gavaldà J, et al. Feasibility, tolerability, and outcomes of nebulized liposomal amphotericin B for Aspergillus infection prevention in lung transplantation. J Heart Lung Transplant 2010; 29:523-530.
48. Minari A, Husni R, Avery RK, et al. The incidence of invasive aspergillosis among solid organ transplant recipients and implications for prophylaxis in lung transplants. Transpl Infect Dis 2002; 4:195-200. (Pubitemid 36142805)
49. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46:1813-1821.
50. Bhaskaran A, Mumtaz K, Singer LG, et al. Anti-fungal prophylaxis in lung transplant recipients (LTRs): a meta-analysis of cohort studies. J Heart Lung Transplant 2013; 32:S130.
51. Avery R. Antifungal prophylaxis in lung transplantation. Semin Respir Crit Care Med 2011; 32:717-726.
52. Marks DI, Pagliuca A, Kibbler CC, et al. Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation. Br J Haematol 2011; 155:318-327.
53. Hamacher J, Spiliopoulos A, Kurt AM, Nicod LP. Preemptive therapy with azoles in lung transplant patients. Geneva Lung Transplantation Group. Eur Respir J 1999; 13:180-186. (Pubitemid 29079241)
54. Pinney MF, Rosenberg AF, Hampp C, et al. Invasive fungal infections in lung transplant recipients not receiving routine systemic antifungal prophylaxis: 12-year experience at a university lung transplant center. Pharmacotherapy 2011; 31:537-545.
55. Singh N, Limaye AP, Forrest G, et al. Late-onset invasive aspergillosis in organ transplant recipients in the current era. Med Mycol 2006; 44:445-449. (Pubitemid 44173328)
56. Luong M-L, Hosseini-Moghaddam SM, Singer LG, et al. Risk factors for voriconazole hepatotoxicity at 12 weeks in lung transplant recipients. Am J Transplant 2012; 12:1929-1935.
57. Mikulska M, Novelli A, Aversa F, et al. Voriconazole in clinical practice. J Chemother 2012; 24:311-327.
58. Feist A, Lee R, Osborne S, et al. Increased incidence of cutaneous squamous cell carcinoma in lung transplant recipients taking long-term voriconazole. J Heart Lung Transplant 2012; 31:1177-1181.
59. Zwald FO, Spratt M, Lemos BD, et al. Duration of voriconazole exposure: an independent risk factor for skin cancer after lung transplantation. Dermatol Surg 2012; 38:1369-1374.
60. Singer JP, Boker A, Metchnikoff C, et al. High cumulative dose exposure to voriconazole is associated with cutaneous squamous cell carcinoma in lung transplant recipients. J Heart Lung Transplant 2012; 31:694-699.
61. Chen L, Mulligan ME. Medication-induced periostitis in lung transplant patients: periostitis deformans revisited. Skeletal Radiol 2010; 40:143-148.
62. Han K, Capitano B, Bies R, et al. Bioavailability and population pharmacokinetics of voriconazole in lung transplant recipients. Antimicrob Agents Chemother 2010; 54:4424-4431.
63. Billaud EM, Guillemain R, Berge M, et al. Pharmacological considerations for azole antifungal drug management in cystic fibrosis lung transplant patients. Med Mycol 2010; 48:S52-S59.
64. Singh N, Aguado JM, Bonatti H, et al. Zygomycosis in solid organ transplant recipients: a prospective, matched case-control study to assess risks for disease and outcome. J Infect Dis 2009; 200:1002-1011.
65. Safdar A, Ma J, Saliba F, et al. Drug-induced nephrotoxicity caused by amphotericin B lipid complex and liposomal amphotericin B. Medicine 2010; 89:236-244.
66. Solé A. Invasive fungal infections in lung transplantation: role of aerosolised amphotericin B. Int J Antimicrob Agents 2008; 32:S161-S165.
67. Monforte V, Ussetti P, López R, et al. Nebulized liposomal amphotericin B prophylaxis for Aspergillus infection in lung transplantation: pharmacokinetics and safety. J Heart Lung Transplant 2009; 28:170-175.
68. Drew R. Potential role of aerosolized amphotericin B formulations in the prevention and adjunctive treatment of invasive fungal infections. Int J Antimicrob Agents 2006; 27 (Suppl 1):36-44. (Pubitemid 43775909)
69. Husain S, Capitano B, Corcoran T, et al. Intrapulmonary disposition of amphotericin B after aerosolized delivery of amphotericin B lipid complex (Abelcet; ABLC) in lung transplant recipients. Transplantation 2010; 90: 1215-1219.
70. Monforte V, Román A, Gavaldà J, et al. Nebulized amphotericin B concentration and distribution in the respiratory tract of lung-transplanted patients. Transplantation 2003; 75:1571-1574. (Pubitemid 36597298)
71. Monforte V, López-Sánchez A, Zurbano F, et al. Prophylaxis with nebulized liposomal amphotericin B for Aspergillus infection in lung transplant patients does not cause changes in the lipid content of pulmonary surfactant. J Heart Lung Transplant 2013; 32:313-319.
72. Salavert M. Prophylaxis, preemptive or empirical antifungal therapy: which is best in nonlung transplant recipients? Int J Antimicrob Agents 2008; 32:S149-S153.
73. Kubak BM. Fungal infection in lung transplantation. Transpl Infect Dis 2002; 4 (Suppl 3):24-31. (Pubitemid 34832433)
74. Husain S, Kwak EJ, Obman A, et al. Prospective assessment of Platelia Aspergillus galactomannan antigen for the diagnosis of invasive aspergillosis in lung transplant recipients. Am J Transplant 2004; 4:796-802. (Pubitemid 38637580)
75. Leeflang MM, Debets-Ossenkopp YJ, Visser CE, et al. Galactomannan detection for invasive aspergillosis in immunocompromized patients. Cochrane Database Syst Rev 2008; 4:CD007394.
76. Lass-Flörl C, Gunsilius E, Gastl G, et al. Diagnosing invasive aspergillosis during antifungal therapy by PCR analysis of blood samples. J Clin Microbiol 2004; 42:4154-4157. (Pubitemid 39296138)
77. Husain S, Paterson DL, Studer SM, et al. Aspergillus galactomannan antigen in the bronchoalveolar lavage fluid for the diagnosis of invasive aspergillosis in lung transplant recipients. Transplantation 2007; 83:1330-1336. (Pubitemid 46800308)
78. Bhaskaran A, Singer LG, Yinka A, et al. Efficacy of BAL galactomannan (GM) and culture based pre-emptive antifungal therapy (PET) in lung transplant recipients (LTRs). J Heart Lung Transplant 2013; 32:S49.
79. Tolman JA, Wiederhold NP, McConville JT, et al. Inhaled voriconazole for prevention of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 2009; 53:2613-2615.
80. Thompson GR, Wiederhold NP. Isavuconazole: a comprehensive review of spectrum of activity of a new triazole. Mycopathologia 2010; 170:291-313.